A new hemagglutination method for blood grouping

Information

  • Research Project
  • 8833912
  • ApplicationId
    8833912
  • Core Project Number
    R44HL117557
  • Full Project Number
    2R44HL117557-02
  • Serial Number
    117557
  • FOA Number
    PA-14-071
  • Sub Project Id
  • Project Start Date
    2/1/2013 - 12 years ago
  • Project End Date
    4/30/2017 - 7 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    9/1/2015 - 9 years ago
  • Budget End Date
    4/30/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/14/2015 - 9 years ago

A new hemagglutination method for blood grouping

DESCRIPTION (provided by applicant): The long-term goal of the proposed research is to develop a novel quantitative particle agglutination technology for improving the performance of blood typing assays. The conventional hemagglutination blood typing assays have serious drawbacks such as limited sensitivity, long time of incubation, subjectivity and large amount of reagents. It is in this context that we propose to develop a new technology, which is free from the aforementioned limitations of the conventional hemagglutination assays. The proposed immunoassay is a sensitive and rapid method that utilizes inexpensive instrumentation. The Specific Aims of Phase II are: 1) To further explore all variables affecting the performance of the new blood typing detection assays and optimize the performance of the assay; 2) To design and assemble an ?rototype of the device for performing of several blood typing assays simultaneously. The ?rototype is intended to test the design of every technical element of the system before it is implemented in the final pre- production prototype; 3) To validate the detection assays for determination of blood groups (including weak D group and C, c, E, e and K antigens) and expected antibodies (reverse typing); To examine a statistically significant number of clinical samples for each assay, and carry out statistical analysis and demonstrate reproducibility of the obtained results; To compare performance of the conventional and newly developed assays. Significantly, the new method presents a general approach for enhancement and detection of agglutination of particles of different origin, including latex, silic microparticles, and biological cells.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    495210
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:495210\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALLIED INNOVATIVE SYSTEMS, LLC
  • Organization Department
  • Organization DUNS
    139604156
  • Organization City
    HILLSBOROUGH
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    088441936
  • Organization District
    UNITED STATES